CAH 2025 | Professor Jin Lu: Advancing High-Quality Development in Multiple Myeloma Care through Standardized Treatment, Data Integration, and Optimized Follow-up

CAH 2025 | Professor Jin Lu: Advancing High-Quality Development in Multiple Myeloma Care through Standardized Treatment, Data Integration, and Optimized Follow-up

2025.07.16
From June 20 to 22, the 19th Annual Meeting of the Chinese Medical Doctor Association Hematology Branch and the 2025 China Hematology Conference (CAH 2025) was held in the historic city of Xi’an. As a major academic event in China’s hematology community, the conference maintained its core mission of “serving clinical practice,” with a strong focus on treatment standardization, practical application, and multicenter collaboration, fostering deep integration of academic exchange and clinical implementation. During the event, Oncology Frontier – Hematology Frontier interviewed Professor Jin Lu from Peking University People's Hospital, Executive Chair of CAH 2025, for an in-depth conversation on the highlights of this year’s conference and the development of multiple myeloma (MM) care in China.
Prof. Philip Kwong: New Strategies and Emerging Horizons in the Management of mHSPC

Prof. Philip Kwong: New Strategies and Emerging Horizons in the Management of mHSPC

2025.07.10
The “2025 Pujiang Prostate Cancer Academic Conference,” held from June 27 to 28 in Shanghai, was jointly organized with the Annual Meeting of the Chinese Society of Clinical Oncology Prostate Cancer Committee (CSCO-PC), the Chinese Anti-Cancer Association Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Annual Conference of the Chinese Prostate Cancer Consortium (CPCC). With the theme “Global Vision · Chinese Practice · Precision Breakthrough,” the event attracted numerous domestic and international experts to share the latest advances and real-world experiences in prostate cancer.
Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented

Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented

2025.07.08
At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP regimen) as a first-line treatment for metastatic triple-negative breast cancer (mTNBC). Results showed a median PFS of 11.8 months and median OS of 27.1 months, with manageable toxicity. The second study, an ongoing trial (Abstract #TPS1122), aims to predict treatment response to T-DXd in HER2-positive breast cancer brain metastases using68Ga-FAPI PET-CT to assess tumor metabolic heterogeneity. The trial is actively recruiting patients.This article specifically introduces two studies.